

TTFields (NovoTTF-200T) LUNAR

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**



**Other adjustments**



TTFields (NovoTTF-200T) LUNAR

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response


**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies

Therapeutic Indication: Addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with non-small cell lung cancer (NSCLC) after disease progression on or following platinum-based treatment

Experimental Arm: TTFields (NovoTTF-200T) + Standard systemic therapy (investigator's choice of immune checkpoint inhibitor [nivolumab, pembrolizumab, or atezolizumab] or docetaxel)

Control Arm: Standard therapy alone



